Abaxys Therapeutics SA
Abaxys Therapeutics reported total assets of €1.31m at the end of the 2025 financial year (annual accounts filed with the NBB on 17 Aug 2026).
By total assets for 2025, Abaxys Therapeutics ranks in the top half of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Abaxys Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +188 % Total assets +57 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Abaxys Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 17 Aug 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 23 Sep 2024
- Year ended 31 Dec 2022filed on 01 Sep 2023
- Year ended 31 Dec 2021filed on 30 Aug 2022
Abaxys Therapeutics's financial analysis
- Solvency79.8%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Abaxys Therapeutics
Abaxys Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0644.674.965
- VAT number
- BE0644674965
- Peppol
- Registered · 0208:0644674965 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 18 Dec 2015
- Registered office
- 1495 Villers-la-Ville
- Latest accounts
- 2025 · filed on 17 Aug 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Abaxys Therapeutics (SA) has been based in Villers-la-Ville since 2015, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 75,495 € and equity of €1.04m; its revenue is not published. Its solvency stands at 79.8%, above the median of its sector (57.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Abaxys Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- Protea Biopharma NV Research and experimental development on natural sciences and engineering Asse · balance sheet €1.30m
- Stam Agro Research and experimental development on natural sciences and engineering Dendermonde · balance sheet €1.86m
- Inhatarget Therapeutics Research and experimental development on natural sciences and engineering Charleroi · balance sheet €2.16m
- Dendrogenix Research and experimental development on natural sciences and engineering Liège · balance sheet €5.28m
- BiometrIQ Research and experimental development on natural sciences and engineering Kortrijk · balance sheet €1.65m
- Puxano Research and experimental development on natural sciences and engineering Ghent · balance sheet €2.43m
- Sticon Research and experimental development on natural sciences and engineering Tielt · balance sheet 507,688 €
- THERAtRAME Research and experimental development on natural sciences and engineering Liège · balance sheet €2.67m
Frequently asked questions about Abaxys Therapeutics
What is the revenue of Abaxys Therapeutics?
Abaxys Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Abaxys Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0644674965 for Abaxys Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0644.674.965.
Where is the registered office of Abaxys Therapeutics?
According to the CBE register, the registered office of Abaxys Therapeutics is in 1495 Villers-la-Ville.
What is the equity of Abaxys Therapeutics?
At the close of the 2025 financial year, the equity of Abaxys Therapeutics amounts to 1,043,150 €, a solvency of 79.8% of total assets.
Who manages Abaxys Therapeutics?
The register lists 4 active mandates at Abaxys Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Abaxys Therapeutics within its sector?
By total assets for 2025, Abaxys Therapeutics ranks in the top half of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of Abaxys Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →